Mizuho Reiterates Buy on Iovance Biotherapeutics, Maintains $30 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Mara Goldstein has reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $30 price target.
June 16, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Mara Goldstein reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $30 price target.
The Buy rating and maintained $30 price target by Mizuho analyst Mara Goldstein on Iovance Biotherapeutics (NASDAQ:IOVA) indicates a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100